FDA
-
-
-
-
-
-
-
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
-
-
-
-
-
-
-
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
MBX Biosciences names Laurie Stelzer to board as audit chair
-
-
-
-
-
-
-
Microbix Announces Initiation of Normal Course Issuer Bid
-
-
-
-
-
-
-
Microbix Presenting at Muskoka Capital Event
-
-
-
-
-
-
-
Microbix Hosts Ontario Minister Stephen Crawford
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on MBX Biosciences Inc (MBX)
-
329,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

